ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury (SPINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02917291
Recruitment Status : Recruiting
First Posted : September 28, 2016
Last Update Posted : August 21, 2018
Sponsor:
Collaborator:
Histocell S.L.
Information provided by (Responsible Party):
Ferrer Internacional S.A.

September 20, 2016
September 28, 2016
August 21, 2018
December 2016
April 2019   (Final data collection date for primary outcome measure)
Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord [ Time Frame: One year ]
Same as current
Complete list of historical versions of study NCT02917291 on ClinicalTrials.gov Archive Site
  • Changes from baseline in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC [ Time Frame: One year ]
  • Changes from baseline in the functional assessment of Spinal Cord Independence Measure (SCIM III) [ Time Frame: Day 28 and Day 90 ]
  • Changes from baseline in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test. [ Time Frame: Day 28 and Day 90 ]
  • Changes from baseline in Motor-Evoked Potentials (MEP) electrophysiological assessment test [ Time Frame: Day 28 and Day 90 ]
  • Changes from baseline in nerve conduction velocities electrophysiological assessment test [ Time Frame: Day 28 and Day 90 ]
  • Changes from baseline in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC [ Time Frame: One year ]
  • Changes from baseline in the functional assessment of Spinal Cord Independence Measure (SCIM III) [ Time Frame: 28d and 90d ]
  • Changes from baseline in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test. [ Time Frame: 28d and 90d ]
  • Changes from baseline in Motor-Evoked Potentials (MEP) electrophysiological assessment test [ Time Frame: 28d and 90d ]
  • Changes from baseline in nerve conduction velocities electrophysiological assessment test [ Time Frame: 28d and 90d ]
Not Provided
Not Provided
 
Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury
Clinical Trial of Phase 1/2 to Evaluate the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of FAB117-HC, a Drug Whose Active Ingredient is HC016, Allogeneic Adipose Derived Adult Mesenchymal Stem Cells Expanded and Pulsed With H2O2, in Acute Traumatic SCI Patients.
The main objective of the study is the evaluation of the safety and tolerability of FAB117-HC (a medicinal product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, HC016 cells) administered at a single-time point to patients with acute thoracic traumatic spinal cord injury (SCI). The study will also include initial exploration of potential clinical efficacy. Dose levels of 20 million and 40 million cells will be administered.

FAB117-HC is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.

The main purpose of this study is to evaluate the safety and tolerability of a single administration of FAB117-HC using: a) two sequential escalating doses administered between 72 and 120 hours post-injury, to patients with acute traumatic SCI with ASIA Impairment Scale (AIS) grade A; and b) the determined maximum tolerated dose administered between 48 and 72 h post-injury to patients with AIS grading of A or B. The study includes also initial exploration of efficacy.

Treatment is administered by intramedullary injection into the injured spinal cord, during the decompression and stabilization surgery (DSS) of the fracture. DSS is routinely performed on almost all SCI patients.

The study has been divided into two phases:

Phase 1 (open label): 6 AIS A patients with lesion located between D1 and D12 will be included in 2 sequential cohorts.

Phase 2 (randomized, controlled, double-blind): 40 AIS A or B patients with lesion located between D1 and D12, will be randomly divided into two groups (control and treated) that will be balanced in AIS grade.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Acute Traumatic Spinal Cord Injury
  • Drug: FAB117-HC
    (Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 3 patients in cohort 2 (40 million cells)
  • Other: Control group
    (Ph 2) No treatment will be administered
  • Drug: FAB117-HC
    (Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
  • Experimental: FAB117-HC (Ph 1)
    Patients with acute traumatic spinal cord injury grading AIS A (6 patients)
    Intervention: Drug: FAB117-HC
  • Control group (Ph 2)
    Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
    Intervention: Other: Control group
  • Experimental: FAB117-HC (Ph 2)
    Patients with acute traumatic spinal cord injury grading AIS A or B (20 patients)
    Intervention: Drug: FAB117-HC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
46
Same as current
January 2020
April 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Phase 1 (2 Cohorts)

  1. Male or female subjects ≥ 18 to ≤ 65 years.
  2. ASIA impairment grade A.
  3. Either a level of injury between D1-D11 both inclusive, and D12 without motor zone of partial preservation (ZPP) (cohorts 1 and 2).
  4. Single traumatic spinal cord injury as defined by MRI.
  5. Injury occurred between 72 and 120h before undergoing DSS and treatment.
  6. Clinically and haemodynamically stable enough to undergo DSS.
  7. Able to give informed consent either in writing or orally in the presence of a witness.

Phase 2 (2 Groups)

  1. Male or female subjects ≥ 18 to ≤ 65 years.
  2. ASIA impairment grade A or B.
  3. An injury between D1 and D11, both inclusive, and D12 without motor zone of partial preservation (ZPP).
  4. Single traumatic spinal cord injury as defined by MRI.
  5. Injury occurring between 24 and 72 h before undergoing DSS and treatment.
  6. Clinically and haemodynamically stable enough to undergo DSS.
  7. Able to give informed consent either in writing or orally in the presence of a witness.

Exclusion Criteria:

  1. Participated in a previous clinical study and received an investigational product within 28 days of SCI (within 5 years of SCI if the investigational product is a cell-based medicine).
  2. Radiological or MRI or DSS evidence of complete spinal cord transection or equivalent severe lesion or abnormality.
  3. Inability to unequivocally identify the injection sites.
  4. Multiple injuries to the neurological spinal cord at different levels.
  5. Patients with any of these additional conditions:

    1. Penetrating spinal cord injuries.
    2. Associated trauma or injury to the brachial and / or lumbosacral plexus.
  6. Active infection in the surgical area.
  7. Haemodynamic instability contraindicating DSS procedure in the time frame defined for inclusion in the trial.
  8. Multiple organ failure.
  9. Significant head injury (Score on the Glasgow scale less than or equal to 13 and / or abnormal MRI/CT, meaning oedema, axonal lesion and/or haemorrhage) or other injury that in the investigator's opinion is sufficient to interfere with the assessment of spinal cord function or compromise the validity of patient data.
  10. Patients undergoing mechanical ventilation that does not allow a prior clinical examination.
  11. Inability to communicate with the neurological examiner so that the validity of patient data could be unreliable.
  12. Coma or significant impairment in the level of consciousness, including unconsciousness due to sedative-analgesic medications, that interferes with the performance or interpretation of assessments specific in the protocol.
  13. Preexisting or current significant diseases such as hepatitis C, HIV, epilepsy, neoplastic disease or other diseases that could cause neurological deficits including syphilis, myelopathy, and polyneuropathy.
  14. Background or acute episode of Guillain-Barre syndrome.
  15. History of meningitis or meningoencephalitis.
  16. History of current autoimmune disease.
  17. Patients with history of severe thrombophilia or under anticoagulant or antiplatelet pharmacological therapy.
  18. Presence of any psychiatric illness, as defined by the DSM-IV-TR, or medically unstable illness which can reasonably be expected to pose an increased risk to on participating in the study, or which causes a significant deterioration of the clinical course of the patient. Secondary depression is expressly excluded.
  19. Drug abuse as defined by DSM-IV-TR during the 6 months prior to SCI.
  20. Pregnant women or women of childbearing age who are not using an appropriate method of contraception and, moreover, are not willing to continue to use it for the duration of the trial. If the patient is menopausal or sterile, it must be documented in the medical record.
  21. Women who are breastfeeding if unwilling to stop at the time of recruitment.
  22. History of allergy with anaphylactic shock.
  23. Patients with known hypersensitivity to any of the excipients of FAB117-HC.
  24. Patients with known hypersensitivity to penicillin, streptomycin, enzymes (trypsin or collagenase), bovine serum or DMSO.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
No
Contact: Andrés G Fernández, PhD ferreradvancedbiotherapeutics@ferrer.com
Spain
 
 
NCT02917291
FAB117-CT-01
Yes
Not Provided
Not Provided
Ferrer Internacional S.A.
Ferrer Internacional S.A.
Histocell S.L.
Not Provided
Ferrer Internacional S.A.
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP